Conference Coverage

Ibrutinib outperforms bendamustine and rituximab in older CLL patients

Publish date: December 2, 2018

 

REPORTING FROM ASH 2018

SOURCE: Woyach JA et al. ASH 2018, Abstract 6.

Pages

Recommended Reading

Novel options for treating hairy cell leukemia
B-Cell Lymphoma ICYMI
Some mutation testing can be useful at CLL diagnosis
B-Cell Lymphoma ICYMI
Ibrutinib plus obinutuzumab gets priority review in CLL/SLL
B-Cell Lymphoma ICYMI
Ibrutinib discontinuation harms survival in CLL
B-Cell Lymphoma ICYMI
Sandoz halts pursuit of U.S. approval for rituximab biosimilar
B-Cell Lymphoma ICYMI
Variant not linked to CLL in Southeast Europe
B-Cell Lymphoma ICYMI
CLL: The initial work-up
B-Cell Lymphoma ICYMI
Consider treatment, testing when CLL symptoms emerge
B-Cell Lymphoma ICYMI
ASH 2018 coming attractions look at the big picture
B-Cell Lymphoma ICYMI
Cortactin expression aids in CLL-MCL differential
B-Cell Lymphoma ICYMI

Related Articles